For patients with severe calcification or complex non-calcified plaques, we investigate wether PCCT can enable non-invasive, in vivo precise differentiation and quantitative measurement of plaque components (e.g., spotty calcification, necrotic core, fibrous tissue). Further we also study wether these quantitative imaging features can independently predict the risk of MACE in the short term and long term
Adult patients (≥18 years) with clinically diagnosed coronary artery disease or undergoing CCTA for chest pain/heart failure symptoms.
Able and willing to provide informed consent and complete scheduled follow-up visits.
History of iodine contrast agent allergy.
Severe renal insufficiency (eGFR < 30 mL/min/1.73 m²).
History of prior coronary artery bypass grafting (CABG).
Pregnant or lactating women
coronary artery disease patients referred to photon-counting CT examination
Cohort
Prospective
there is no intervention in this study
Other interventionthere is no intervention
Major Adverse Cardiovascular Events, MACE
Non-fatal myocardial infarction Non-fatal stroke Cardiovascular death Revascularization Acute heart failure
Click on the lead sponsor to view all of their trials.
This trial is not recruiting at the moment. You can still explore other options:
